All In Biotech

Drug Trial Radar · NCT04989699

Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration

A Prospective Multicenter, Double-Masked, Randomized, Parallel-Group, Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI (Axitinib Implant) for Intravitreal Use in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)

Last checked: Nov 20, 2026Latest source record: Jan 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

21

Actual

Start

Jul 28, 2021

Primary completion

Feb 6, 2023

Study completion Dec 18, 2023

Sponsor

Lead sponsor
Ocular Therapeutix, Inc.Industry
Sponsor type
Industry
First posted
Aug 4, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the safety, tolerability, and efficacy of OTX-TKI for intravitreal use in subjects with Neovascular Age-Related Macular Degeneration

Conditions

  • Neovascular Age-Related Macular Degeneration

Interventions

  • OTX-TKI/ShamDrug

    OTX-TKI is one dose so subsequent visits will be sham to maintain the mask

  • Aflibercept/ShamDrug

    Aflibercept administered every 8 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and TolerabilityTime frame: Through study completion, an average of 1 year

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Ocular Therapeutix

    Bakersfield, California

  • Ocular Therapeutix

    Oxnard, California

  • Ocular Therapeutix

    Altamonte Springs, Florida

  • Ocular Therapeutix

    St. Petersburg, Florida

  • Ocular Therapeutix

    Reno, Nevada

  • Ocular Therapeutix

    The Woodlands, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.